Nonpharmacologic versus pharmacologic treatment of adult patients with major depressive disorder: A clinical practice guideline from the American College of Physicians

Annals of Internal Medicine

Volumn 164, Issue 5, 2016, Pages 350-359

  Qaseem, Amir ^a   Barry, Michael J ^c   Kansagara, Devan ^b   Forciea, Mary Ann ^d   Denberg, Thomas D ^d   Boyd, Cynthia ^d   Chow, R Dobbin ^d   Fitterman, Nick ^d   Harris, Russell P ^d   Humphrey, Linda L ^d   Manaker, Scott ^d   McLean, Robert ^d   Vijan, Sandeep ^d   Wilt, Timothy ^d  

^a AMERICAN COLLEGE OF PHYSICIANS   (United States)

^b PORTLAND VA MEDICAL CENTER   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; OMEGA 3 FATTY ACID; PAROXETINE; S ADENOSYLMETHIONINE; SERTRALINE; ANTIDEPRESSANT AGENT;

ACUPUNCTURE; ADULT; ALTERNATIVE MEDICINE; COGNITIVE THERAPY; EXERCISE; FUNCTIONAL STATUS; HOSPITALIZATION; HUMAN; HYPERICUM PERFORATUM; MAJOR DEPRESSION; MONOTHERAPY; PHYSICIAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROBLEM SOLVING; PSYCHODYNAMIC PSYCHOTHERAPY; PSYCHOTHERAPY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; REVIEW; SYSTEMATIC REVIEW; TREATMENT RESPONSE; YOGA; DEPRESSIVE DISORDER, MAJOR; KINESIOTHERAPY; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; COGNITIVE THERAPY; COMPLEMENTARY THERAPIES; DEPRESSIVE DISORDER, MAJOR; EXERCISE THERAPY; HUMANS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX;

EID: 84959294611     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/M15-2570     Document Type: Review

References (71)

1. Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud C, Ezzati M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2163-96. [PMID: 23245607] doi:10.1016/S0140-6736(12)61729-2
2. Greenberg PE, Kessler RC, Birnbaum HG, Leong SA, Lowe SW, Berglund PA, et al. The economic burden of depression in the United States: how did it change between 1990 and 2000? J Clin Psychiatry. 2003;64:1465-75. [PMID: 14728109]
3. Kessler RC, Berglund P, Demler O, Jin R, Koretz D, Merikangas KR, et al; National Comorbidity Survey Replication. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA. 2003;289:3095-105. [PMID: 12813115]
4. Centers for Disease Control and Prevention. FastStats: depression. Atlanta, GA: Centers for Disease Control and Prevention; 2015. Accessed at www.cdc.gov/nchs/fastats/depression.htm on 6 January 2016.
5. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Arlington, VA: American Psychiatric Publishing; 2013.
6. Gartlehner G, Gaynes BN, Amick HR, Asher G, Morgan LC, Coker-Schwimmer M, et al. Nonpharmacological Versus Pharmacological Treatments for Adult Patients With Major Depressive Disorder. Comparative effectiveness review no. 161. (Prepared by the RTI International-University of North Carolina Evidence-based Practice Center under contract no. 290-2012-00008-I.) AHRQ publication no. 15(16)-EHC031-EF. Rockville, MD: Agency for Healthcare Research and Quality; 2015. Accessed at www.effectivehealthcare.ahrq.gov/ehc/products/568/2155/major-depressive-disorder-report-151202.pdf on 6 January 2016.
7. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001;16:606-13. [PMID: 11556941]
8. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56-62. [PMID: 14399272]
9. Gartlehner G, Gaynes BN, Amick HR, Asher GN, Morgan LC, Coker-Schwimmer E, et al. Comparative benefits and harms of antidepressant, psychological, complementary, and exercise treatments for major depression: an evidence report for a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2016. [Epub ahead of print] doi:10.7326/M15-1813
10. Qaseem A, Snow V, Owens DK, Shekelle P; Clinical Guidelines Committee of the American College of Physicians. The development of clinical practice guidelines and guidance statements of the American College of Physicians: summary of methods. Ann Intern Med. 2010;153:194-9. [PMID: 20679562] doi:10.7326/0003-4819-153-3-201008030-00010
11. David D, Szentagotai A, Lupu V, Cosman D. Rational emotive behavior therapy, cognitive therapy, and medication in the treatment of major depressive disorder: a randomized clinical trial, posttreatment outcomes, and six-month follow-up. J Clin Psychol. 2008;64: 728-46. [PMID: 18473339] doi:10.1002/jclp.20487
12. DeRubeis RJ, Hollon SD, Amsterdam JD, Shelton RC, Young PR, Salomon RM, et al. Cognitive therapy vs medications in the treatment of moderate to severe depression. Arch Gen Psychiatry. 2005; 62:409-16. [PMID: 15809408]
13. Hegerl U, Hautzinger M, Mergl R, Kohnen R, Schütze M, Scheunemann W, et al. Effects of pharmacotherapy and psychotherapy in depressed primary-care patients: a randomized, controlled trial including a patients' choice arm. Int J Neuropsychopharmacol. 2010; 13:31-44. [PMID: 19341510] doi:10.1017/S1461145709000224
14. Mynors-Wallis LM, Gath DH, Day A, Baker F. Randomised controlled trial of problem solving treatment, antidepressant medication, and combined treatment for major depression in primary care. BMJ. 2000;320:26-30. [PMID: 10617523]
15. Dimidjian S, Hollon SD, Dobson KS, Schmaling KB, Kohlenberg RJ, Addis ME, et al. Randomized trial of behavioral activation, cognitive therapy, and antidepressant medication in the acute treatment of adults with major depression. J Consult Clin Psychol. 2006;74: 658-70. [PMID: 16881773]
16. Lam RW, Parikh SV, Ramasubbu R, Michalak EE, Tam EM, Axler A, et al. Effects of combined pharmacotherapy and psychotherapy for improving work functioning in major depressive disorder. Br J Psychiatry. 2013;203:358-65. [PMID: 24029535] doi:10.1192/bjp.bp .112.125237
17. Menchetti M, Rucci P, Bortolotti B, Bombi A, Scocco P, Kraemer HC, et al; DEPICS group. Moderators of remission with interpersonal counselling or drug treatment in primary care patients with depression: randomised controlled trial. Br J Psychiatry. 2014;204:144-50. [PMID: 24311553] doi:10.1192/bjp.bp.112.122663
18. Frank E, Cassano GB, Rucci P, Thompson WK, Kraemer HC, Fagiolini A, et al. Predictors and moderators of time to remission of major depression with interpersonal psychotherapy and SSRI pharmacotherapy. Psychol Med. 2011;41:151-62. [PMID: 20380782] doi: 10.1017/S0033291710000553
19. Blom MB, Jonker K, Dusseldorp E, Spinhoven P, Hoencamp E, Haffmans J, et al. Combination treatment for acute depression is superior only when psychotherapy is added to medication. Psychother Psychosom. 2007;76:289-97. [PMID: 17700049]
20. Salminen JK, Karlsson H, Hietala J, Kajander J, Aalto S, Markkula J, et al. Short-term psychodynamic psychotherapy and fluoxetine in major depressive disorder: a randomized comparative study. Psychother Psychosom. 2008;77:351-7. [PMID: 18701831] doi:10.1159/000151388
21. Bastos AG, Guimarães LS, Trentini CM. Neurocognitive changes in depressed patients in psychodynamic psychotherapy, therapy with fluoxetine and combination therapy. J Affect Disord. 2013;151: 1066-75. [PMID: 24103853] doi:10.1016/j.jad.2013.08.036
22. Sun H, Zhao H, Ma C, Bao F, Zhang J, Wang DH, et al. Effects of electroacupuncture on depression and the production of glial cell line-derived neurotrophic factor compared with fluoxetine: a randomized controlled pilot study. J Altern Complement Med. 2013;19: 733-9. [PMID: 23647408] doi:10.1089/acm.2011.0637
23. Huang Y, Htut WM, Li D, Tang A, Li Q, Shi N, et al. Studies on the clinical observation and cerebral glucose metabolism in depression treated by electro-scalp acupuncture compared to fluoxetine. International Journal of Clinical Acupuncture. 2005;14:7-26.
24. Qu SS, Huang Y, Zhang ZJ, Chen JQ, Lin RY, Wang CQ, et al. A 6-week randomized controlled trial with 4-week follow-up of acupuncture combined with paroxetine in patients with major depressive disorder. J Psychiatr Res. 2013;47:726-32. [PMID: 23498306] doi: 10.1016/j.jpsychires.2013.02.004
25. Zhang WJ, Yang XB, Zhong BL. Combination of acupuncture and fluoxetine for depression: a randomized, double-blind, shamcontrolled trial. J Altern Complement Med. 2009;15:837-44. [PMID: 19678773] doi:10.1089/acm.2008.0607
26. Hypericum Depression Trial Study Group. Effect of Hypericum perforatum (St. John's wort) in major depressive disorder: a randomized controlled trial. JAMA. 2002;287:1807-14. [PMID: 11939866]
27. Szegedi A, Kohnen R, Dienel A, Kieser M. Acute treatment of moderate to severe depression with hypericum extract WS 5570 (St. John's wort): randomised controlled double blind non-inferiority trial versus paroxetine. BMJ. 2005;330:503. [PMID: 15708844]
28. Brenner R, Azbel V, Madhusoodanan S, Pawlowska M. Comparison of an extract of hypericum (LI 160) and sertraline in the treatment of depression: a double-blind, randomized pilot study. Clin Ther. 2000;22:411-9. [PMID: 10823363]
29. Schrader E. Equivalence of St. John's wort extract (Ze 117) and fluoxetine: a randomized, controlled study in mild-moderate depression. Int Clin Psychopharmacol. 2000;15:61-8. [PMID: 10759336]
30. Gastpar M, Singer A, Zeller K. Comparative efficacy and safety of a once-daily dosage of hypericum extract STW3-VI and citalopram in patients with moderate depression: a double-blind, randomised, multicentre, placebo-controlled study. Pharmacopsychiatry. 2006; 39:66-75. [PMID: 16555167]
31. Gastpar M, Singer A, Zeller K. Efficacy and tolerability of hypericum extract STW3 in long-term treatment with a once-daily dosage in comparison with sertraline. Pharmacopsychiatry. 2005;38:78-86. [PMID: 15744631]
32. Behnke K, Jensen GS, Graubaum HJ, Gruenwald J. Hypericum perforatum versus fluoxetine in the treatment of mild to moderate depression. Adv Ther. 2002;19:43-52. [PMID: 12008860]
33. Bjerkenstedt L, Edman GV, Alken RG, Mannel M. Hypericum extract LI 160 and fluoxetine in mild to moderate depression: a randomized, placebo-controlled multi-center study in outpatients. Eur Arch Psychiatry Clin Neurosci. 2005;255:40-7. [PMID: 15538592]
34. van Gurp G, Meterissian GB, Haiek LN, McCusker J, Bellavance F. St. John's wort or sertraline? Randomized controlled trial in primary care. Can Fam Physician. 2002;48:905-12. [PMID: 12053635]
35. Fava M, Alpert J, Nierenberg AA, Mischoulon D, Otto MW, Zajecka J, et al. A double-blind, randomized trial of St. John's wort, fluoxetine, and placebo in major depressive disorder. J Clin Psychopharmacol. 2005;25:441-7. [PMID: 16160619]
36. Blumenthal JA, Babyak MA, Doraiswamy PM, Watkins L, Hoffman BM, Barbour KA, et al. Exercise and pharmacotherapy in the treatment of major depressive disorder. Psychosom Med. 2007;69: 587-96. [PMID: 17846259]
37. Hoffman BM, Blumenthal JA, Babyak MA, Smith PJ, Rogers SD, Doraiswamy PM, et al. Exercise fails to improve neurocognition in depressed middle-aged and older adults. Med Sci Sports Exerc. 2008;40:1344-52. [PMID: 18580416] doi:10.1249/MSS .0b013e31816b877c
38. Blumenthal JA, Babyak MA, Moore KA, Craighead WE, Herman S, Khatri P, et al. Effects of exercise training on older patients with major depression. Arch Intern Med. 1999;159:2349-56. [PMID: 10547175]
39. Babyak M, Blumenthal JA, Herman S, Khatri P, Doraiswamy M, Moore K, et al. Exercise treatment for major depression: maintenance of therapeutic benefit at 10 months. Psychosom Med. 2000; 62:633-8. [PMID: 11020092]
40. Rush AJ, Trivedi MH, Wisniewski SR, Stewart JW, Nierenberg AA, Thase ME, et al; STAR∗D Study Team. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med. 2006;354:1231-42. [PMID: 16554525]
41. Lenox-Smith AJ, Jiang Q. Venlafaxine extended release versus citalopram in patients with depression unresponsive to a selective serotonin reuptake inhibitor. Int Clin Psychopharmacol. 2008;23: 113-9. [PMID: 18408525] doi:10.1097/YIC.0b013e3282f424c2
42. Thase ME, Friedman ES, Biggs MM, Wisniewski SR, Trivedi MH, Luther JF, et al. Cognitive therapy versus medication in augmentation and switch strategies as second-step treatments: a STAR∗D report. Am J Psychiatry. 2007;164:739-52. [PMID: 17475733]
43. Trivedi MH, Fava M, Wisniewski SR, Thase ME, Quitkin F, Warden D, et al; STAR∗D Study Team. Medication augmentation after the failure of SSRIs for depression. N Engl J Med. 2006;354:1243-52. [PMID: 16554526]
44. Segal ZV, Kennedy S, Gemar M, Hood K, Pedersen R, Buis T. Cognitive reactivity to sad mood provocation and the prediction of depressive relapse. Arch Gen Psychiatry. 2006;63:749-55. [PMID: 16818864]
45. Moradveisi L, Huibers MJ, Renner F, Arasteh M, Arntz A. Behavioural activation v. antidepressant medication for treating depression in Iran: randomised trial. Br J Psychiatry. 2013;202:204-11. [PMID: 23391727] doi:10.1192/bjp.bp.112.113696
46. Dekker JJ, Koelen JA, Van HL, Schoevers RA, Peen J, Hendriksen M, et al. Speed of action: the relative efficacy of short psychodynamic supportive psychotherapy and pharmacotherapy in the first 8 weeks of a treatment algorithm for depression. J Affect Disord. 2008;109: 183-8. [PMID: 18061276]
47. Barber JP, Barrett MS, Gallop R, Rynn MA, Rickels K. Short-term dynamic psychotherapy versus pharmacotherapy for major depressive disorder: a randomized, placebo-controlled trial. J Clin Psychiatry. 2012;73:66-73. [PMID: 22152401] doi:10.4088/JCP.11m06831
48. Zhang ZJ, Chen HY, Yip KC, Ng R, Wong VT. The effectiveness and safety of acupuncture therapy in depressive disorders: systematic review and meta-analysis. J Affect Disord. 2010;124:9-21. [PMID: 19632725] doi:10.1016/j.jad.2009.07.005
49. Chen J, Lin W, Wang S, Wang C, Li G, Qu S, et al. Acupuncture/electroacupuncture enhances anti-depressant effect of Seroxat: the Symptom Checklist-90 scores. Neural Regen Res. 2014;9:213-22. [PMID: 25206803] doi:10.4103/1673-5374.125353
50. Jazayeri S, Tehrani-Doost M, Keshavarz SA, Hosseini M, Djazayery A, Amini H, et al. Comparison of therapeutic effects of omega-3 fatty acid eicosapentaenoic acid and fluoxetine, separately and in combination, in major depressive disorder. Aust N Z J Psychiatry. 2008;42:192-8. [PMID: 18247193] doi:10.1080/00048670701827275
51. Gertsik L, Poland RE, Bresee C, Rapaport MH. Omega-3 fatty acid augmentation of citalopram treatment for patients with major depressive disorder. J Clin Psychopharmacol. 2012;32:61-4. [PMID: 22198441] doi:10.1097/JCP.0b013e31823f3b5f
52. Mischoulon D, Price LH, Carpenter LL, Tyrka AR, Papakostas GI, Baer L, et al. A double-blind, randomized, placebo-controlled clinical trial of S-adenosyl-L-methionine (SAMe) versus escitalopram in major depressive disorder. J Clin Psychiatry. 2014;75:370-6. [PMID: 24500245] doi:10.4088/JCP.13m08591
53. Papakostas GI, Crawford CM, Scalia MJ, Fava M. Timing of clinical improvement and symptom resolution in the treatment of major depressive disorder. A replication of findings with the use of a double-blind, placebo-controlled trial of Hypericum perforatum versus fluoxetine. Neuropsychobiology. 2007;56:132-7. [PMID: 18259086] doi:10.1159/000115779
54. Harrer G, Schmidt U, Kuhn U, Biller A. Comparison of equivalence between the St. John's wort extract LoHyp-57 and fluoxetine. Arzneimittelforschung. 1999;49:289-96. [PMID: 10337446]
55. Institute of Medicine Committee on Quality of Health Care in America. Crossing the quality chasm: a new health system for the 21st century. Washington, DC: National Academies Pr; 2001. Accessed at www.nap.edu/read/10027/chapter/1 on 6 January 2016.
56. Mojtabai R, Olfson M. National patterns in antidepressant treatment by psychiatrists and general medical providers: results from the national comorbidity survey replication. J Clin Psychiatry. 2008; 69:1064-74. [PMID: 18399725]
57. Gartlehner G, Gaynes BN, Hansen RA, Thieda P, DeVeaugh-Geiss A, Krebs EE, et al. Comparative benefits and harms of secondgeneration antidepressants: background paper for the American College of Physicians. Ann Intern Med. 2008;149:734-50. [PMID: 19017592]
58. Qaseem A, Snow V, Denberg TD, Forciea MA, Owens DK; Clinical Efficacy Assessment Subcommittee of American College of Physicians. Using second-generation antidepressants to treat depressive disorders: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2008;149: 725-33. [PMID: 19017591]
59. Gartlehner G, Hansen RA, Morgan LC, Thaler K, Lux L, Van Noord M, et al. Comparative benefits and harms of secondgeneration antidepressants for treating major depressive disorder: an updated meta-analysis. Ann Intern Med. 2011;155: 772-85. [PMID: 22147715] doi:10.7326/0003-4819-155-11-201112060-00009
60. Gartlehner G, Hansen RA, Morgan LC, Thaler K, Lux LJ, Van Noord M, et al. Second-Generation Antidepressants in the Pharmacologic Treatment of Adult Depression: An Update of the 2007 Comparative Effectiveness Review. Comparative effective review no. (Prepared by the RTI-UNC Evidence-based Practice Center under contract no. 290-2007-10056-I.) AHRQ publication no. 12-EHC012-EF. Rockville, MD: Agency for Healthcare Research and Quality; 2011. Accessed at www.effectivehealthcare.ahrq.gov/ehc/products/210/863/CER46-Antidepressants-update-20111206.pdf on 6 January 2016.
61. Hammerness P, Basch E, Ulbricht C, Barrette EP, Foppa I, Basch S, et al; Natural Standard Research Collaboration. St. John's wort: a systematic review of adverse effects and drug interactions for the consultation psychiatrist. Psychosomatics. 2003;44:271-82. [PMID: 12832592]
62. Knüppel L, Linde K. Adverse effects of St. John's Wort: a systematic review. J Clin Psychiatry. 2004;65:1470-9. [PMID: 15554758]
63. Mueller SC, Majcher-Peszynska J, Uehleke B, Klammt S, Mundkowski RG, Miekisch W, et al. The extent of induction of CYP3A by St. John's wort varies among products and is linked to hyperforin dose. Eur J Clin Pharmacol. 2006;62:29-36. [PMID: 16341856]
64. Markowitz JS, Donovan JL, DeVane CL, Taylor RM, Ruan Y, Wang JS, et al. Effect of St. John's wort on drug metabolism by induction of cytochrome P450 3A4 enzyme. JAMA. 2003;290: 1500-4. [PMID: 13129991]
65. Mills E, Montori VM, Wu P, Gallicano K, Clarke M, Guyatt G. Interaction of St. John's wort with conventional drugs: systematic review of clinical trials. BMJ. 2004;329:27-30. [PMID: 15231618]
66. Miller LG. Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions. Arch Intern Med. 1998;158:2200-11. [PMID: 9818800]
67. Hong H, Carlin BP, Shamliyan TA, Wyman JF, Ramakrishnan R, Sainfort F, et al. Comparing Bayesian and frequentist approaches for multiple outcome mixed treatment comparisons. Med Decis Making. 2013;33:702-14. [PMID: 23549384] doi:10.1177/0272989X13481110
68. Jones B, Roger J, Lane PW, Lawton A, Fletcher C, Cappelleri JC, et al; PSI Health Technology Special Interest Group, Evidence Synthesis sub-team. Statistical approaches for conducting network meta-analysis in drug development. Pharm Stat. 2011;10:523-31. [PMID: 22213533] doi:10.1002/pst.533
69. Berkman ND, Lohr KN, Ansari M, McDonagh M, Balk E, Whitlock E, et al. Grading the Strength of a Body of Evidence When Assessing Health Care Interventions for the Effective Health Care Program of the Agency for Healthcare Research and Quality: An Update. AHRQ publication no. 13(14)-EHC130-EF. Rockville, MD: Agency for Healthcare Research and Quality; 2013. Accessed at www.effective healthcare.ahrq.gov/ehc/products/457/1752/methods-guidance-grading-evidence-131118.pdf on 6 January 2016.
70. Viswanathan M, Ansari MT, Berkman ND, Chang S, Hartling L, McPheeters LM, et al. Assessing the Risk of Bias of Individual Studies in Systematic Reviews of Health Care Interventions. AHRQ publication no. 12-EHC047-EF. Rockville, MD: Agency for Healthcare Research and Quality; 2012. Accessed at www.effectivehealthcare .ahrq.gov/ehc/products/322/998/MethodsGuideforCERs-Viswanathan-IndividualStudies.pdf on 6 January 2016.
71. Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al; Cochrane Bias Methods Group. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011; 343:d5928. [PMID: 22008217] doi:10.1136/bmj.d5928